To: Ron who wrote (2703 ) 9/23/2003 12:45:23 AM From: JMarcus Respond to The investor presentation reported on preliminary results (the trial is not yet fully enrolled) from the second phase (the high dose group) of the P 1/2 telomerase inhibition prostate cancer trial (being performed at Duke Univeristy) of Geron's telomerase cancer vaccine product. In the high dose group (received 6 vaccinations instead of 3), the total number of anti-telomerase T-cells generated from the vaccine amounted to 1-2% of the total T-cell population of the immune suppressed cancer patients. That threshold is higher than any T-cell response produced by any trial of any cancer vaccine product. That is the level of vaccine reactivity that you see with measles or mumps vaccinations. The duration of the vaccine response appears to be long-lived. At 13 weeks, the T-cell response level was higher than the peak response level achieved with the low dose group. The difference between the low dose and high dose group was simply doubling the number of injections (same dosage level) from three weekly injections to six weekly injections.
